Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study

Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We investigated the efficacy and sa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Li, Ling, Kong, Fei, Zhang, Lei, Li, Xin, Fu, Xiaorui, Wang, Xinhua, Wu, Jingjing, Zhang, Fangwen, Ren, Liangliang, Zhang, Mingzhi
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Phase II Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7575486/
https://ncbi.nlm.nih.gov/pubmed/32363427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00925-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados